PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
November 1, 2025Neuro-OncologyOpen Access

PATH-77. Clinical and molecular predictors of survival and treatment response in AYA/adults with BRAF-V600 mutant high-grade glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMohamed SheriefNCNancy ChenLCLucy Chen

Discussion

Loading...

Member takes

Overview

Observational cohort identified predictors of treatment response and survival in BRAF V600E-mutant high-grade glioma, suggesting targeted therapy insights.

Key Points

  • To identify clinical and molecular predictors of survival and treatment response in patients with BRAF-V600E high-grade glioma.
  • Identified 98 BRAF-altered gliomas from a single-institution prospective cohort
  • Included patients with histopathologic grade 3 or 4 and confirmed BRAF V600E mutation
  • Analyzed clinical follow-up and treatment regimens including radiation and BRAF inhibitors.
  • 54% of patients were female and 71% Caucasian
  • Median progression-free survival with temozolomide was 15.5 months
  • Molecular characterization of tumors revealed a significant percentage with unmethylated MGMT promoter.

Cite This Study

Sherief et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc3581ddhttps://doi.org/10.1093/neuonc/noaf201.1029
View Full Paper
Ask AI
Bookmark
Share